CDT · Conduit Pharmaceuticals Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $1.53M | $1.86M | $1.31M | - | $3.09M | $25.0K | $128.0K | - | $38.0K |
| SG&A | - | $5.50M | $3.09M | $2.70M | - | $2.72M | $3.12M | $2.83M | - | $1.07M |
| Total Operating Expenses | - | $7.03M | $4.95M | $4.01M | - | $5.81M | $3.14M | $2.96M | - | $1.07M |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | ($7.03M) | ($4.95M) | ($4.01M) | - | ($5.81M) | ($3.14M) | ($2.96M) | - | ($1.07M) |
| Interest Expense | - | $100.0K | $100.0K | $100.0K | - | $49.0K | $40.0K | $119.0K | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($7.12M) | ($6.03M) | ($5.15M) | - | ($6.46M) | ($5.38M) | ($3.55M) | - | $1.99M |
| EPS - Basic | - | ($329.00) | ($1092.00) | ($3960.00) | - | ($21000.00) | ($21000.00) | ($15000.00) | - | ($9000.00) |
| EPS - Diluted | - | ($329.00) | ($1092.00) | ($3960.00) | - | ($21000.00) | ($21000.00) | ($15000.00) | - | $0.00 |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.51M | $3.84M | $3.33M | $2.13M | $554.0K | $71.0K | $219.0K | $1.84M | $4.23M | $8.64M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.91M | $613.0K | $1.25M | $714.0K | $1.43M | $1.90M | $1.06M | $117.0K | $215.0K | $35.0K |
| Current Assets | $4.38M | $7.09M | $6.39M | $5.95M | $2.71M | $1.40M | $1.60M | $3.16M | $5.73M | $10.44M |
| Total Assets | $5.65M | $8.55M | $7.99M | $7.32M | $4.19M | $2.99M | $3.31M | $4.92M | $7.22M | $12.02M |
| Current Liabilities | $12.82M | $4.26M | $4.41M | $4.55M | $10.74M | $11.98M | $2.86M | $1.98M | $1.80M | $4.60M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $12.82M | $4.27M | $4.46M | $4.63M | $10.99M | $12.11M | $8.77M | $8.02M | $7.68M | $13.10M |
| Stockholders' Equity | ($7.17M) | $4.28M | $3.53M | $2.69M | ($6.79M) | ($9.12M) | ($5.46M) | ($3.10M) | ($457.0K) | ($1.08M) |
| Retained Earnings | ($68.33M) | ($47.00M) | ($39.88M) | ($34.25M) | ($29.10M) | ($26.70M) | ($20.23M) | ($14.85M) | ($11.30M) | ($13.08M) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($4.33M) | - | - | - | ($2.36M) | - | - |
| Investing Cash Flow | - | - | - | ($4.0K) | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | $5.93M | - | - | - | - | - | - |
| CapEx | - | - | - | $4.0K | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | ($4.33M) | - | - | - | - | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | 0.84 | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -83.2% | -75.5% | -70.3% | - | -215.9% | -162.9% | -72.2% | - | 16.5% |
| Return on equity | - | -166.4% | -170.8% | -191.5% | - | 70.9% | 98.6% | 114.6% | - | -183.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.34 | 1.66 | 1.45 | 1.31 | 0.25 | 0.12 | 0.56 | 1.59 | 3.18 | 2.27 |
| Quick ratio | 0.34 | 1.66 | 1.45 | 1.31 | 0.25 | 0.12 | 0.56 | 1.59 | 3.18 | 2.27 |
| Cash ratio | 0.12 | 0.90 | 0.76 | 0.47 | 0.05 | 0.01 | 0.08 | 0.93 | 2.35 | 1.88 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -70.3x | -49.5x | -40.1x | - | -118.6x | -78.5x | -24.8x | - | - |
| Equity multiplier | -0.79 | 2.00 | 2.26 | 2.72 | -0.62 | -0.33 | -0.61 | -1.59 | -15.81 | -11.12 |
| Liabilities / Assets | 2.27 | 0.50 | 0.56 | 0.63 | 2.62 | 4.05 | 2.65 | 1.63 | 1.06 | 1.09 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | 17.2x | 172.6x | 3388.3x | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -21.0% | -57.7% | -35.7% | - | -443.6% | -672.9% | -482.4% | - | -333.9% |
| Net income growth (YoY) | - | -10.2% | -12.0% | -44.9% | - | - | -1466.1% | - | - | 859.9% |
| EPS growth (YoY) | - | 98.4% | 94.8% | 73.6% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -5.5% | - | - | - | -1386.4% | -743.5% | 10.0% | 43.4% | 89.4% | 70.8% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CONDUIT PHARMACEUTICALS INC. against the 5 most active filers in the same SIC group.